Canntab Therapeutics — Investor Presentation (January 2022)
15 slides from Canntab Therapeutics's investor presentation, January 2022
Slide 1: Corporate Presentation
CORPORATE PRESENTATION OUR ONLINE STORE IS OPEN! CSE: PILL | OTCQB: CTABF | FSE:TBF1 CSE: PILL | OTCQB: CTABF | FSE:TBF1 January 2022 Canntab Therapeutics Limited © 2022
Slide 2: Disclaimer
DISCLAIMER This presentation contains "forward-looking information" within the meaning of applicable Canadian securities legislation. Generally, forward-looking information can be identified by the use of forward-looking terminology such as "plans", "expects", or "does not expect", "is expected", "b
Slide 3: What We Do
WHAT WE DO We are the leading innovator of cannabinoid and terpene blends in hard pill form for therapeutic applications. OUR ONLINE STORE IS OPEN! Three patents granted in the United States, Canada, and Australia. Seven pending patent applications internationally. Sales license granted by H
Slide 4: Strong IP Portfolio
STRONG IP PORTFOLIO 3 patents granted, with 7 more patents pending in the United States and Canada covering our proprietary processes and hard pill formulations for, Extended Release In August 2019, the Geneva-based International Sustained Release Preliminary Report on Patentability (“IPRP”) ind
Slide 5: Proprietary Process
PROPRIETARY PROCESS Our patent pending proprietary processes allows us to create hard pill formulations that starts with the highest quality cannabis oil in water emulsions, a unique process in the industry to date. Oil emulsion >> wet granulation >> dried granulation >> blending >> tablet pressing
Slide 6: Meeting Medical Standards
MEETING MEDICAL STANDARDS Current delivery mechanisms such as smoking or vaping cannabis, consuming edibles, gel caps, oils and tincture (droppers) do not provide the medical community, including Doctors, patients or the average consumer, with an attractive and professional cannabis solution. CANNTA
Slide 7: Therapeutic Window
THERAPEUTIC WINDOW Smoking cannabis can result in a large initial dose of the drug followed by a precipitous drop. Edibles dosing is unpredictable, making it difficult to maintain therapeutic relief. Our solution, an extended release (XR) tablets with flash melt technology, quickly brings the patien
Slide 8: How We Generate Revenue
HOW WE GENERATE REVENUE As of March 15th 2021, we’ve manufactured almost two million hard pills at our Markham Ontario facility. These hard pills are for our partners, including MediPharm (Toronto) and Cann Global (Australia), and for our online store. Go to Canntab.ca to learn more. Our revenue str
Slide 9: Tablet Economics
TABLET ECONOMICS Note: Sensitivity Analysis is meant to be illustrative and is not intended to used as a forecast. Canntab Therapeutics Limited © 2021 CSE: PILL | OTCQB: CTABF | FSE:TBF1 9
Slide 10: Capitalization
CAPITALIZATION Canntab Therapeutics Limited © 2021 CSE: PILL | OTCQB: CTABF | FSE:TBF1 10
Slide 11: 1-Year Chart
1-YEAR CHART As of market close, December 10th, 2021 Canntab Therapeutics Limited © 2021 CSE: PILL | OTCQB: CTABF | FSE:TBF1 11
Slide 12: Management Team
MANAGEMENT TEAM Richard Goldstein, Co-Founder Larry Latowsky Chief Financial Officer Chief Executive Officer Founder First Republic Capital, Co-Founder Fraser Former President and CEO of Drug Trading. McKenzie, former EVP/Head of IB at Standard Securities. Former President and CEO of Katz Grou
Slide 13: Summary
SUMMARY Our new online store is open, and includes a telehealth department that facilitates registration and customer care throughout the purchase process. Our Instacann THC 5mg will launch on the OCS website on January 25th, 2022. Full scale hard pill manufacturing is ongoing at our facility
Slide 14: Looking at the Future
LOOKING AT THE FUTURE Online sale begin with our own platform at Canntab.ca, and the Ontario Cannabis Store on January 20th, and January 24th respectively. Blood level studies in Canada and Australia will be conducted in 2022, as the first steps towards further clinical trials designed to advanc
Slide 15: Contact Us
CONTACT US Richard Goldstein Co-founder & Chief Financial Officer (647) 209-3279 Richard@Canntab.ca Larry Latowsky Frank Candido Chief Executive Officer Business Development Consultant (416) 458-6491 (514) 969-5530 Larry@Canntab.ca Frank@Canntab.ca Canntab Therapeutics Limited © 2021 CSE: PILL | OTC
Canntab Therapeutics — Investor Presentation (January 2022) on 6ix